A new gene therapy has been used to help treat patients who suffer from a rare inherited eye disorder, and which also causes blindness. There is hope that the NHS treatment will be able to halt sight loss and improve vision.
NICE Approval
The treatment costs £600,000, however NHS England has agreed a discount price with its manufacturer, Novartis. Luxturna (voretigene neparvovec) has been approved by the National Institute for Health and Care Excellence (NICE), which estimates that just under 90 people in England will be eligible for the new treatment.
Please register or login to comment!
Register now Login